Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, esophageal, and gastroesophageal junction cancers.
Barrett's esophagus was defined as columnar epithelium visible above the gastroesophageal junction. Patients who received continuous PPI therapy for ≥1 year and were adequately followed up were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback